Hematology — ASCP Exam Prep Platelet Production, Structure & Function

Master megakaryopoiesis, platelet anatomy, and primary hemostasis mechanisms for ASCP BOC hematology exam.

ASCPprep.com | Hematology

Chapter 7 — PLATELET PRODUCTION, STRUCTURE & FUNCTION

ASCP Board Exam · Lab-Focused Study Guide

Megakaryocytopoiesis · Endomitosis · TPO · Ultrastructure · Receptors · Granules · Adhesion, Aggregation, Secretion · Activation Pathways · Practice Questions

1 · Priority Table & Quick Foundation

Topic	Priority	Why It’s Tested
Platelet count, MPV, smear appearance, splenic pool (⅓)	HIGH	Reference values, hypersplenism and post-splenectomy questions
Megakaryocyte progenitors (BFU-Meg, CFU-Meg, LD-CFU-Meg) and endomitosis	HIGH	‘Which progenitor undergoes endomitosis?’ is a classic item
MK-I / MK-II / MK-III stage features	HIGH	Marrow morphology; 2–4 megakaryocytes per 10× field
TPO (liver, MPL receptor, inverse relation to platelet mass) and other cytokines	HIGH	TPO source/regulation; TPO mimetics; IL-11
Adhesion receptors: GP Ib/IX/V (VWF), GP VI and α2β1 (collagen), GP IIb/IIIa (fibrinogen)	HIGH	Receptor–ligand matching; Bernard-Soulier vs Glanzmann
α-granule vs dense granule contents	HIGH	‘Which is stored in dense granules?’ (ADP, ATP, serotonin, Ca²⁺)
Adhesion vs aggregation vs secretion; VWF role; ADAMTS-13	HIGH	Definitions and the order of primary hemostasis
Eicosanoid pathway: COX → TXA₂ vs endothelial prostacyclin; cAMP/calcium	HIGH	Aspirin mechanism and platelet inhibition questions
Phosphatidylserine flip and coagulation complexes (tenase, prothrombinase)	HIGH	Link from platelets to secondary hemostasis
Ultrastructure: glycocalyx, SCCS, DTS, microtubules, microfilaments	MEDIUM	‘Which organelle sequesters calcium?’ → DTS
Seven-transmembrane receptors (PAR1/4, P2Y₁/P2Y₁₂, TP, α2, IP) and G proteins	MEDIUM	Receptor/agonist pairs; P2Y₁₂ drugs
Reticulated (stress) platelets / immature platelet fraction	MEDIUM	Indicates increased production
IP₃–DAG pathway, pleckstrin, protein kinase C	MEDIUM	Second messenger recall
Transcription factors (GATA-1, FOG1, RUNX1, NF-E2, MYB), flow markers by stage	LOW	Names only

🎯 KEY POINT — Where to spend your time

Focus: reference numbers, endomitosis and LD-CFU-Meg, TPO, the four receptor–ligand pairs, granule contents, the adhesion → aggregation → secretion sequence, TXA₂ vs prostacyclin, and PS exposure. Skim: transcription factor names, flow marker timelines, G-protein subtypes beyond ‘Gi lowers cAMP / Gs raises cAMP / Gq raises IP₃-DAG’.

Quick Foundation — from zero

Platelets are tiny anucleate cell fragments (~2.5 µm) that plug holes in injured vessels — primary hemostasis.
They come from giant marrow cells, megakaryocytes (30–50 µm), which copy their DNA many times without dividing (endomitosis) to build a huge cytoplasm.
Megakaryocytes sit against marrow sinuses and push out bead-like proplatelet strands that shed platelets into the blood.
Thrombopoietin (TPO), made mainly by the liver, drives the whole process; platelets themselves remove TPO, so fewer platelets = more free TPO.
At a wound, platelets adhere (to collagen via VWF), aggregate (to each other via fibrinogen), and secrete granule contents that recruit more platelets and support clotting.
Activated platelets flip phosphatidylserine outward — the surface where coagulation factor complexes assemble.

💡 Analogy

A megakaryocyte is a factory that never splits — it adds more machinery (DNA copies) and keeps growing, then extrudes a conveyor belt (proplatelet) that drops products (platelets) into the river (sinus). At a leak, platelets act like a sandbag team: first they grab the riverbank (adhesion), then they link arms (aggregation), then they shout for help and hand out cement (secretion, coagulation surface).

🏥 Why this matters clinically

Mucocutaneous bleeding (petechiae, purpura, gum or nose bleeds) means a platelet or VWF problem. Knowing each receptor, granule and pathway lets you link a lab result — low count, giant platelets, failed aggregation to one agonist — to a specific cause.

Concept	Plain-English Explanation
Endomitosis	DNA copies without cell division (no telophase, no cytokinesis) → polyploid megakaryocyte
Thrombocytopoiesis	Shedding of platelets from proplatelet processes
Adhesion	Platelets sticking to non-platelet surfaces (subendothelial collagen via VWF)
Aggregation	Platelets sticking to each other (fibrinogen bridges on GP IIb/IIIa)
Secretion (release)	Emptying granule contents after activation
Agonist	A ligand that activates the platelet (ADP, thrombin, collagen, TXA₂, epinephrine)
Outside-in vs inside-out	Outside-in: receptor signal travels into the cell. Inside-out: internal signal changes a surface receptor’s affinity
White vs red clot	White = platelets + VWF (arteries). Red = platelets, VWF, fibrin, RBCs (veins)

2 · Core Content Tables

2.1 Platelets — Key Numbers

Feature	Details
Count	150–400 × 10⁹/L; slightly higher in women. Over 65 y: men 122–350, women 140–379 × 10⁹/L
Smear	7–21 platelets per 100× oil field in the RBC monolayer; circular to irregular, lavender, granular; ~2.5 µm
MPV	8–10 fL (impedance); volume distribution is log-normal with a large-platelet subpopulation; MPV heterogeneity reflects random variation, not age
Shape	Biconvex discs in blood; ’round up’ in EDTA
Splenic pool	Spleen holds ~⅓ of platelets (count reflects ⅔); released in demand (inflammation, injury, surgery, plateletpheresis). Hypersplenism → relative thrombocytopenia
Production	~10⁸ megakaryocytes make ~10¹¹ platelets/day; turnover 8–9 days; can rise up to 10-fold with high consumption (e.g., ITP)

🧪 PRE-ANALYTICAL — Platelet count & MPV*

EDTA whole blood; mix well and avoid clots (clotted samples falsely lower counts)
EDTA-dependent platelet clumping or platelet satellitism → falsely low count; check the smear feathered edge and recollect in sodium citrate (correct count ×1.1 for dilution)
MPV rises with EDTA storage as platelets swell — analyze within a consistent time window
Giant platelets may be counted as RBCs by impedance; microcytic RBC fragments may be counted as platelets

2.2 Megakaryocytes & Their Location

Feature	Details
Size / nucleus	Largest marrow cells, 30–50 µm; multilobulated nucleus; abundant granular cytoplasm; polyploid
Frequency	<0.5% of marrow cells; 2–4 per 10× low-power field on a normal aspirate
Location	Cluster with HSCs in vascular niches, on the abluminal side of venous sinus endothelial cells; also in the lungs
Release	Proplatelet processes pierce through or between endothelial cells → shed platelets into the sinus; naked nuclei eaten by macrophages
Platelets per megakaryocyte	2,000–4,000

2.3 Megakaryocyte Progenitors & Endomitosis

Progenitor	Ploidy / Division	Colonies	Note
BFU-Meg (least mature)	Diploid; normal mitosis	Hundreds	From CMP via MEP; GATA-1 + FOG1 drive; MYB opposes (balances with erythropoiesis)
CFU-Meg	Diploid; normal mitosis	Scores	Maintains progenitor pool
LD-CFU-Meg (light-density)	Loses ability to divide; DNA replication continues	—	First stage of endomitosis

Endomitosis

Feature	Details
Definition	Mitosis without telophase and cytokinesis
Mechanism	As GATA-1/FOG1 slow, RUNX1 suppresses Rho/ROCK signaling → too little actin/myosin at the division furrow → no cytokinesis. NF-E2 then drives DNA replication
Ploidy	8N, 16N, even 32N; 128N (five replications) is unusual and may signal disease
Purpose	Multiple DNA copies support synthesis of abundant cytoplasm → thousands of platelets
Measurement	Ploidy by flow cytometry with the nucleic acid dye mepacrine

All three progenitors look like lymphocytes on Wright stain — they are identified by colony behavior or flow cytometry.

2.4 Terminal Megakaryocyte Differentiation

Feature	MK-I (Megakaryoblast)	MK-II (Promegakaryocyte)	MK-III (Megakaryocyte)
% of precursors	20	25	55 (most abundant)
Diameter	14–18 µm	15–40 µm	30–50 µm
Nucleus	Round	Indented (first lobularity at 4N)	Multilobed
Nucleoli	2–6	Variable	Not visible
Chromatin	Homogeneous	Moderately condensed	Deeply/variably condensed
N:C ratio	3:1	1:2	1:4
Mitosis	Absent	Absent	Absent
Endomitosis	Present	Ends	Absent
Cytoplasm	Basophilic	Basophilic and granular	Azurophilic (lavender) and granular
α-granules / dense granules / DMS	Present	Present	Present

The megakaryoblast cannot be reliably distinguished from a myeloblast or pronormoblast by light microscopy; a vague clue is cytoplasmic blebs resembling platelets. The demarcation membrane system (DMS) — channels from the plasma membrane that subdivide the cytoplasm — defines individual platelets. Full ploidy is reached by the end of MK-II.

2.5 Megakaryocyte Membrane Markers (flow cytometry / immunostaining)

Feature	Details
MPL (CD110)	TPO receptor — all stages including platelets
CD34	Stem/progenitor marker — disappears as differentiation proceeds
CD41 (GP IIb portion of αIIbβ3)	Appears on progenitors, present throughout maturation
CD42 (GP Ib, VWF receptor), CD36, CD61, CD62, PF4, VWF	Maturing/mature megakaryocytes
Cytoplasmic proteins	Factor VIII, VWF, fibrinogen by immunostaining in mature megakaryocytes
Other tools	Immunostaining of tissue, flow cytometry, FISH to identify indistinguishable progenitors

2.6 Thrombopoietin (TPO) & Other Cytokines

Feature	Details
TPO	~70,000 Da; 23% homology with EPO; mRNA in kidney, liver, stromal and smooth muscle cells — liver has the most copies = primary source
Receptor	MPL (named after v-mpl, a murine myeloproliferative leukemia oncogene)
Regulation	Plasma TPO is inversely proportional to platelet and megakaryocyte mass — platelets bind and remove TPO (main platelet count control)
Actions	With other cytokines: stem cell → megakaryocyte progenitors → megakaryoblasts; proliferation and maturation; but not thrombocytopoiesis itself
TPO mimetics	Romiplostim (peptide MPL agonist, FDA 2008) and eltrombopag (nonpeptide, binds a different MPL site, FDA 2011) raise platelets, e.g., in ITP
IL-3	Synergizes with TPO for early stem cell differentiation
IL-6, IL-11	With TPO: endomitosis, maturation, thrombocytopoiesis. Oprelvekin (IL-11 mimetic, 1997) for chemotherapy-induced thrombocytopenia
Other synergists	Stem cell factor (kit ligand), GM-CSF, G-CSF, EPO, acetylcholinesterase-derived MSGP
Inhibitors	PF4, β-thromboglobulin, neutrophil-activating peptide 2, IL-8; ↓ FOG1, GATA-1, NF-E2

Cytokine	Progenitors	Megakaryocytes	Late Maturation	Thrombocytopoiesis	Clinical Use
TPO	+	+	+	0	Available (mimetics)
IL-3	+	+	0	—	—
IL-6	0	0	+	+	—
IL-11	0	+	+	+	Available

2.7 Reticulated (Stress) Platelets

Feature	Details
When	Released in compensation for thrombocytopenia — early, rapid proplatelet release
Size	Diameter >6 µm; MPV 12–14 fL
Shape	Round up in EDTA; in citrate they are cylindrical and beaded (like proplatelet fragments)
Contents	Free ribosomes and fragments of rough ER (like RBC reticulocytes)
Measurement	Nucleic acid dyes (e.g., thiazole orange) on profiling instruments — may be more useful than MPV. Dense granules can take up the dye and falsely raise the count
Clinical	Indicate ↑ production (peripheral destruction) — e.g., ITP; may be prothrombotic and linked to cardiovascular risk

🧪 PRE-ANALYTICAL — Reticulated platelets / IPF*

EDTA whole blood; analyze within the manufacturer’s stability window — platelets swell and dye uptake changes
High IPF with low count = peripheral destruction/consumption; low IPF with low count = marrow failure

2.8 Platelet Ultrastructure

Feature	Details
Plasma membrane	Phospholipid bilayer + cholesterol. Outer: phosphatidylcholine, sphingomyelin. Inner: phosphatidylinositol, phosphatidylethanolamine, phosphatidylserine. PI supplies arachidonic acid; PS flips outward on activation → surface for factor VIII/IX (tenase) and X/V (prothrombinase)
Glycocalyx	20–30 nm — thicker than on WBCs/RBCs; glycoproteins, proteoglycans; adsorbs albumin, fibrinogen, other plasma proteins; negative charge repels other cells
Surface-connected canalicular system (SCCS)	Spongelike invaginations of the membrane → stores hemostatic proteins, increases surface; route of endocytosis and α-granule secretion
Dense tubular system (DTS)	Remnant of rough ER, next to SCCS; sequesters Ca²⁺; holds phospholipase A₂, cyclooxygenase, thromboxane synthetase, phospholipase C — the platelet’s ‘control center‘
Microtubules	Circumferential bundle of 8–20 tubules (tubulin) under the membrane → maintains discoid shape; disassemble in cold or with colchicine (platelets round up) and reassemble at 37 °C; move inward on activation to expel granules
Microfilaments	Actin (20–30% of platelet protein): globular at rest, filamentous and contractile when Ca²⁺ rises; plus intermediate filaments (desmin, vimentin) → shape change, pseudopods, secretion

2.9 Adhesion & Aggregation Receptors

Receptor	Family / CD	Ligand	Key Points
GP Ia/IIa (α2β1)	Integrin; CD29, CD49b	Collagen	Avidity upregulated by inside-out signal after collagen binds GP VI
α5β1 / α6β1 / αvβ1	Integrins	Fibronectin / laminin / vitronectin	Further adhesion
GP VI	Immunoglobulin gene family	Collagen	Key collagen receptor — triggers activation, TXA₂ and ADP release
GP IV (CD36)	Unclassified	Collagen, thrombospondin	Collagen receptor
GP Ib/IX/V	Leucine-rich repeat; CD42a–d	VWF (GP Ibα); thrombin	2 Ibα + 2 Ibβ + 2 IX + 1 V; ~25,000 copies; tethering at shear >1000 s⁻¹. Mutation in Ibα, Ibβ or IX → Bernard-Soulier syndrome
GP IIb/IIIa (αIIbβ3)	Integrin; CD41, CD61	Fibrinogen, VWF (also vitronectin, fibronectin — RGD)	Inactive separate units assemble on activation (inside-out after GP VI); required for aggregation. Mutation → Glanzmann thrombasthenia
P-selectin (CD62)	Selectin (on α-granule membrane)	Endothelium, leukocytes, platelets	Moves to surface on activation; flow marker of in vivo activation
FcγRIIA (CD32)	Immunoglobulin	IgG Fc	Role in heparin-induced thrombocytopenia
PECAM (CD31), ICAMs	Immunoglobulin	—	Platelet–WBC/endothelial adhesion; inflammation

🧪 PRE-ANALYTICAL — Platelet function / aggregometry*

3.2% sodium citrate (9:1 blood to anticoagulant), clean venipuncture, discard tube first; room temperature — never refrigerate (cold disassembles microtubules and activates platelets)
Test within ~4 h; avoid aspirin/NSAIDs (7–10 days) and P2Y₁₂ drugs per protocol; lipemia and thrombocytopenia interfere
Plasma TXB₂ is unreliable because platelets release it ex vivo after collection; urine 11-dehydrothromboxane B₂ is the stable, measurable metabolite (Rodak)

2.10 Seven-Transmembrane Receptors (STRs) & G Proteins

Receptor	Ligand	G Protein Effect
PAR1	Thrombin (cleaves)	Gi ↓ cAMP; Gq, G12 ↑ IP₃/DAG
PAR4	Thrombin (cleaves)	Gq, G12 ↑ IP₃/DAG
P2Y₁	ADP	Gq ↑ IP₃/DAG
P2Y₁₂	ADP	Gi ↓ cAMP (target of clopidogrel-type drugs*)
TPα, TPβ	TXA₂	Gq ↑ IP₃/DAG
α2-adrenergic	Epinephrine	Gi ↓ cAMP; potentiates ADP, thrombin, TXA₂; opens Ca²⁺ channels
IP	Prostacyclin (PGI₂)	Gs ↑ cAMP → inhibits activation

PAR1 + PAR4 ≈ 1,800 copies per platelet; ~600 ADP receptors per platelet. Other STRs bind serotonin, PAF, PGE₂, PF4, β-thromboglobulin. G proteins are αβγ trimers that swap GDP for GTP when a ligand binds, then hydrolyze GTP to activate enzymes. Rule: ↓ cAMP = activation; ↑ cAMP = inhibition.

2.11 Platelet Granules

Feature	α-Granules	Dense Granules (Dense Bodies)	Lysosomes
Number	50–80 per platelet	2–7 per platelet	Few
EM appearance	Medium gray	Black, opaque (osmium)	~300 nm
Appear in megakaryocyte	Earlier	Later	—
Release route	Fuse with SCCS	Migrate to plasma membrane	—
Contents	Fibrinogen, factor V, VWF, fibronectin, thrombospondin, albumin, IgG · PF4, β-thromboglobulin (platelet-specific), HMWK, PAI-1, plasminogen, protein C inhibitor, α2-antiplasmin · PDGF, TGF-β, EGF, VEGF · membrane P-selectin, GP IIb/IIIa, GP IV, GP Ib/IX/V	ADP (nonmetabolic; aggregation via P2Y₁/P2Y₁₂), ATP, serotonin (vasoconstrictor), Ca²⁺ and Mg²⁺	Arylsulfatase, β-glucuronidase, acid phosphatase, catalase — digest matrix and debris
Role	Adhesion, aggregation, coagulation, wound repair	Amplify primary hemostasis	Digestion

2.12 Platelet Activation — Adhesion, Aggregation, Secretion

Step	What Happens	Key Molecules
Normal state	Endothelium suppresses hemostasis	Prostacyclin, heparan sulfate, TFPI, nitric oxide, thrombomodulin
1 · Adhesion	Injury exposes collagen; endothelial cells release VWF, which unrolls on collagen → GP Ibα binds VWF (reversible tethering, platelet rolls at high shear) → GP VI binds collagen → outside-in signal releases TXA₂ and ADP → inside-out activation of α2β1 → firm attachment; shape change and spreading	VWF, GP Ib/IX/V, GP VI, α2β1; ADAMTS-13 (liver) digests unused VWF
2 · Aggregation	Tissue factor → thrombin → PAR1/PAR4 → ‘COAT‘ platelet (collagen and thrombin activated). αIIbβ3 assembles and binds fibrinogen/VWF (RGD) → platelet–platelet bridges; P-selectin to surface; pseudopods; PS flips outward → coagulation complexes; platelets form a syncytium	GP IIb/IIIa, fibrinogen, thrombin, P-selectin, PS
3 · Secretion	Actin microfilaments and intermediate filaments contract; microtubules move inward, compressing granules. α-granules and lysosomes release via SCCS; dense granules via plasma membrane	ADP, serotonin, Ca²⁺; fibrinogen, factor V, factor VIII (carried by VWF)
Outcome	White clot (platelets + VWF) in arteries; red clot (platelets, VWF, fibrin, RBCs) in veins	Arterial thrombosis (MI, stroke) vs DVT/PE

Shear rates: venules ~500 s⁻¹, arterioles/capillaries to 5,000 s⁻¹, stenosed arteries up to 40,000 s⁻¹. Above 1,000 s⁻¹ the VWF–GP Ib sequence is required. Adhesion, aggregation and secretion often occur simultaneously.

2.13 Eicosanoid (Cyclooxygenase / Thromboxane) Pathway

Feature	Details
Trigger	Agonists (ADP, thrombin, collagen, epinephrine) → G protein → phospholipase A₂
Step 1	PLA₂ releases arachidonic acid from membrane phosphatidylinositol (carbon 2)
Step 2	Cyclooxygenase (in DTS) → PGG₂ → (peroxidase) PGH₂
Step 3 — platelet	Thromboxane synthase → TXA₂ → binds TPα/TPβ → ↓ adenylate cyclase → ↓ cAMP → Ca²⁺ released from DTS → actin contraction → activation
Step 3 — endothelium	Prostacyclin synthase → PGI₂ → IP receptor → ↑ adenylate cyclase → ↑ cAMP → Ca²⁺ sequestered in DTS → inhibition. Dynamic equilibrium in intact vessels
TXA₂ fate	Half-life 30 seconds → thromboxane B₂ (stable) → liver → urine 11-dehydrothromboxane B₂ (measurable)
Aspirin*	Irreversibly acetylates cyclooxygenase → no TXA₂ for the platelet’s life (7–10 days)
Lab link	Reagent arachidonic acid bypasses the membrane step and enters the pathway directly — used to test aspirin effect*

2.14 IP₃–DAG Pathway

Feature	Details
Trigger	G protein → phospholipase C cleaves phosphatidylinositol 4,5-bisphosphate
IP₃	Releases Ca²⁺ from DTS → actin contraction; may activate PLA₂
DAG	Activates protein kinase C → phosphorylates pleckstrin → regulates actin microfilament contraction
Second messengers	G proteins, eicosanoid pathway, IP₃–DAG, adenylate cyclase, cAMP, intracellular Ca²⁺

*From general hemostasis practice, not stated in Rodak Ch. 13.

3 · Visual Memory Hooks

🧠 Progenitor order
“Big Colonies, Little Divisions” → BFU-Meg (hundreds) → CFU-Meg (scores) → LD-CFU-Meg (endomitosis begins).

🧠 Endomitosis
“Copy, don’t Cut” → DNA replicates, no telophase, no cytokinesis.

🧠 MK stages
“I-Round, II-Indented, III-Lobed” → MK-I round nucleus; MK-II indented; MK-III multilobed, 55%.

🧠 TPO
“Liver Makes Platelets’ Lord — TPO on MPL”; platelets eat TPO, so low count = high TPO.

🧠 Receptor pairs
“Ib Binds VWF, VI Views collagen, IIb/IIIa Is Aggregation”.

🧠 Diseases
“Bernard-Soulier = Big platelets, no Binding VWF (GP Ib)” · “Glanzmann = Glue missing (IIb/IIIa)”.

🧠 Dense granules
“ADP, ATP, Serotonin, Calcium — the Dense four” (plus Mg²⁺).

🧠 α-granules
“Alpha carries the Big proteins: Fibrinogen, Five, VWF, PF4, βTG, PDGF”.

🧠 Granule routes
“Alpha takes the Canal (SCCS); Dense goes to the Door (membrane)”.

🧠 Three steps
“Stick, Clump, Spit” → adhesion, aggregation, secretion.

🧠 DTS
“Dense Tubular = calcium Depot + enzyme Desk” → sequesters Ca²⁺, holds COX and thromboxane synthase.

🧠 TXA₂ vs PGI₂
“Thromboxane Tightens; Prostacyclin Pacifies” → TXA₂ ↓ cAMP (activate); PGI₂ ↑ cAMP (inhibit).

🧠 cAMP rule
“cAMP up, platelets calm; cAMP down, platelets go”.

🧠 PS flip
“PS = Platform for Serine proteases” → tenase and prothrombinase assemble.

🧠 Cold
“Cold Collapses tubules” → platelets round up; never refrigerate function samples.

Pattern Triggers

If you see…	Think…	Because…
Low platelets + large platelets (MPV ↑, >6 µm) + ↑ marrow megakaryocytes	Peripheral destruction (e.g., ITP) with compensatory production	Stress/reticulated platelets released early
Low platelets + ↓ marrow megakaryocytes	Production failure*	Not enough megakaryocytes
Low count + big spleen, normal marrow	Splenic sequestration (hypersplenism)	Spleen normally holds ⅓; more when enlarged
Thrombocytosis after splenectomy*	Loss of the splenic pool	⅓ of platelets no longer sequestered
Low count only in EDTA, clumps at feathered edge	EDTA pseudothrombocytopenia*	Artifact — recollect in citrate
Giant platelets, bleeding, no response to ristocetin*	Bernard-Soulier (GP Ib/IX/V)	Can’t bind VWF
Normal count, no aggregation with ADP/collagen/epinephrine*	Glanzmann thrombasthenia (αIIbβ3)	Can’t bind fibrinogen
Mucocutaneous bleeding, normal platelet count	VWF deficiency (von Willebrand disease) or platelet function defect	VWF is a plasma protein essential for adhesion
Poor aggregation to arachidonic acid, recent aspirin*	Aspirin effect	COX blocked → no TXA₂
↑ P-selectin (CD62) on platelets by flow	In vivo platelet activation	P-selectin moves from α-granules to surface
Thrombocytopenia + thrombosis on heparin	Heparin-induced thrombocytopenia	FcγRIIA (CD32) on platelets binds immune complexes
Patient on romiplostim/eltrombopag	Rising platelets via MPL	TPO receptor agonists

Commonly Confused Pairs

Feature	A	B
Mitosis vs endomitosis	BFU-Meg, CFU-Meg — divide	LD-CFU-Meg onward — DNA copies, no division
Adhesion vs aggregation	Platelet to surface (VWF, collagen)	Platelet to platelet (fibrinogen, IIb/IIIa)
GP Ib/IX/V vs GP IIb/IIIa	VWF; Bernard-Soulier	Fibrinogen; Glanzmann
GP VI vs α2β1	Key collagen receptor; triggers activation	Collagen integrin; affinity raised after GP VI
α-granules vs dense granules	50–80; proteins; via SCCS	2–7; small molecules; via membrane
SCCS vs DTS	Membrane invagination; α-granule secretion route	ER remnant; Ca²⁺ store; eicosanoid enzymes
TXA₂ vs PGI₂	Platelet; activates; ↓ cAMP	Endothelium; inhibits; ↑ cAMP
P2Y₁ vs P2Y₁₂	Gq ↑ IP₃/DAG	Gi ↓ cAMP
White vs red clot	Platelets + VWF; arterial	Plus fibrin and RBCs; venous
TPO vs IL-11	Early and late megakaryopoiesis; not shedding	Endomitosis, maturation and shedding
β-thromboglobulin vs PF4	Found only in platelet α-granules	Neutralizes heparin; suppresses megakaryopoiesis

Timeline & Kinetics Table

Event	Onset	Peak	Duration	Best Exam Use
Platelet life span / turnover	—	—	8–9 days	Why aspirin effect lasts ~a week*
Production boost with consumption	Days*	Up to 10× normal	While demand persists	ITP marrow response
Reticulated platelets	Early in compensation	—	Young platelets	Marker of production
TXA₂	Seconds after activation	—	Half-life 30 s	Why TXB₂/urine metabolite is measured
Microtubules in cold	Minutes*	—	Reassemble at 37 °C	Don’t refrigerate specimens
Ploidy	Endomitosis MK-I → MK-II	8N–32N	Complete by end of MK-II	Stage recognition

4 · Diagnostic Flowcharts

Flowchart 1 — Low platelet count: real or artifact?*

Platelet count low on analyzer	→	Review smear feathered edge and body
Clumps or platelet satellitism around neutrophils	→	EDTA artifact → recollect in sodium citrate
Clotted specimen	→	Recollect
Smear confirms thrombocytopenia	→	Go to Flowchart 2
⚠️ Common mistake: reporting a critical low count without checking the smear for clumps.

Flowchart 2 — True thrombocytopenia: production, destruction, or sequestration?

Confirmed low count + mucocutaneous bleeding	→	Check MPV / reticulated platelets and marrow megakaryocytes
↑ MPV, large platelets >6 µm, ↑ or normal megakaryocytes (e.g., 10–12 per 10× field)	→	Peripheral destruction (e.g., ITP) — marrow compensating
↓ Megakaryocytes, low reticulated platelets	→	Production failure*
Splenomegaly, normal marrow	→	Sequestration (hypersplenism)
⚠️ Common mistake: assuming thrombocytopenia always means marrow failure. In ITP the marrow is working harder, producing up to 10× normal.

Flowchart 3 — Bleeding with normal platelet count (receptor defects)*

Mucocutaneous bleeding, normal count	→	Platelet function testing + VWF studies
Giant platelets, no ristocetin agglutination	→	Bernard-Soulier (GP Ib/IX/V)
No aggregation to ADP, collagen, epinephrine; ristocetin normal	→	Glanzmann thrombasthenia (GP IIb/IIIa)
Low VWF antigen/activity	→	von Willebrand disease — plasma protein deficiency
Only arachidonic acid response absent	→	Aspirin/COX defect
⚠️ Common mistake: labeling VWD as a platelet defect. The platelets are normal; the plasma VWF is missing.

Flowchart 4 — Method selection for platelet evaluation

Need count and size	→	Impedance/optical analyzer (count, MPV) + smear
Need production status	→	Reticulated platelets / IPF (thiazole orange)
Need megakaryocyte identity or ploidy	→	Flow cytometry (CD41, CD42, CD61, MPL; mepacrine for ploidy), immunostaining, FISH
Need in vivo activation	→	Flow for P-selectin (CD62)
Need aspirin/TXA₂ status	→	Urine 11-dehydrothromboxane B₂ (not plasma TXB₂)
⚠️ Common mistake: ordering plasma TXB₂ — platelets release it ex vivo after collection, so it isn’t reliable.

Flowchart 5 — Activation sequence at an injured artery (timing)

Endothelium damaged; collagen exposed; VWF released	→	GP Ibα tethers to VWF (reversible, rolling)
GP VI binds collagen	→	Outside-in: TXA₂ + ADP released → inside-out: α2β1 firm adhesion
Tissue factor → thrombin → PAR1/PAR4	→	COAT platelet; αIIbβ3 binds fibrinogen → aggregation
Granules released; PS flips out	→	Tenase/prothrombinase assemble → fibrin
Result	→	White clot (artery) or red clot (vein)
⚠️ Common mistake: placing aggregation before adhesion. Platelets must first stick to the wall before binding each other.

5 · 25 High-Yield Facts

#	Fact
1	The normal platelet count is 150–400 × 10⁹/L, with MPV 8–10 fL and diameter about 2.5 µm.
2	The spleen sequesters about one-third of circulating platelets.
3	Megakaryocytes are the largest marrow cells (30–50 µm), with 2–4 per 10× field on a normal aspirate.
4	Megakaryocytes lie on the abluminal side of venous sinus endothelial cells.
5	Megakaryocyte progenitors mature from BFU-Meg to CFU-Meg to LD-CFU-Meg.
6	The LD-CFU-Meg is the first stage to undergo endomitosis.
7	Endomitosis is DNA replication without telophase or cytokinesis, producing 8N–32N ploidy.
8	MK-III (megakaryocyte) is the most abundant terminal stage (55%) with a multilobed nucleus.
9	The demarcation membrane system subdivides megakaryocyte cytoplasm into individual platelets.
10	One megakaryocyte sheds 2,000–4,000 platelets; turnover is 8–9 days.
11	TPO is produced mainly by the liver and binds the MPL receptor.
12	Plasma TPO is inversely proportional to platelet and megakaryocyte mass.
13	IL-11 enhances endomitosis, maturation and thrombocytopoiesis; oprelvekin is its mimetic.
14	Reticulated (stress) platelets exceed 6 µm, have MPV 12–14 fL, and signal increased production.
15	Phosphatidylserine flips to the outer membrane on activation to support tenase and prothrombinase.
16	The dense tubular system sequesters calcium and houses the eicosanoid enzymes.
17	Circumferential microtubules maintain the platelet’s discoid shape and disassemble in the cold.
18	GP Ib/IX/V binds VWF; its deficiency causes Bernard-Soulier syndrome.
19	GP VI is the key collagen receptor that triggers activation.
20	GP IIb/IIIa (αIIbβ3) binds fibrinogen for aggregation; its deficiency causes Glanzmann thrombasthenia.
21	Dense granules contain ADP, ATP, serotonin, calcium and magnesium.
22	α-granules contain fibrinogen, factor V, VWF, PF4 and β-thromboglobulin.
23	Adhesion is platelet-to-surface binding; aggregation is platelet-to-platelet binding.
24	Cyclooxygenase and thromboxane synthase convert arachidonic acid to TXA₂, which activates platelets by lowering cAMP.
25	Endothelial prostacyclin (PGI₂) raises platelet cAMP and inhibits activation.

⭐ EXAM TIP — The single most testable pattern

Receptor → ligand → step → disease: GP Ib/IX/V → VWF → adhesion → Bernard-Soulier · GP IIb/IIIa → fibrinogen → aggregation → Glanzmann · GP VI → collagen → activation. And: dense = ADP/ATP/serotonin/Ca²⁺; DTS = calcium store.

Quick Interpretation Table

Lab Finding	Clinical Interpretation
Platelets 35 × 10⁹/L, MPV 13.2 fL, platelets >6 µm, 10–12 megakaryocytes/10× field	Peripheral destruction with increased production (e.g., ITP) — not marrow failure
Platelet count 90 × 10⁹/L with splenomegaly	Consider hypersplenism/sequestration
↑ Immature platelet fraction	Increased production in response to need
↑ CD62 (P-selectin) on circulating platelets	In vivo platelet activation
↑ Urine 11-dehydrothromboxane B₂ despite aspirin	Possible aspirin resistance/nonadherence*
Platelet clumps in EDTA, normal count in citrate	EDTA pseudothrombocytopenia*
Large platelets, normal count, absent ristocetin response	Bernard-Soulier syndrome*

🎴 Flashcards — Active Recall Practice

How it works: tap the card to flip it. Then mark it ✓ Knew It or ✗ Review Again (buttons unlock after flipping). Use 🔀 Shuffle to randomize and 🏁 Finish anytime — your summary appears at the end, and you can drill only the cards you missed.

📝 Practice Quiz — Test Your Knowledge

How it works: tap an answer for each case. You’ll get instant feedback with the full explanation and the examiner’s trap. Your final score appears once all 10 are answered.

🪤 Trap Questions — Beat the Examiner

Harder on purpose. Each question targets a real misconception. After answering you’ll see the correct reasoning, the trap explained, why the examiner wrote it, and the wrong answer most students choose.

8 · Rapid Revision Sheet

📖 READ THIS 2 HOURS BEFORE YOUR EXAM

Numbers

Count 150–400 × 10⁹/L · MPV 8–10 fL
~2.5 µm · 7–21/100× field
Spleen holds ⅓
Turnover 8–9 d · 10¹¹/day · up to 10×
Stress platelets >6 µm, MPV 12–14

Megakaryocytes

30–50 µm · 2–4 per 10× field · <0.5% BM
BFU-Meg → CFU-Meg → LD-CFU-Meg (endomitosis)
MK-I 20% · MK-II 25% · MK-III 55%
8N–32N · endomitosis ends MK-II
2,000–4,000 platelets each

Cytokines

TPO: liver, MPL, inverse to platelet mass
TPO 23% homology with EPO
IL-3 early · IL-6/IL-11 late + shedding
Romiplostim, eltrombopag, oprelvekin
Inhibit: PF4, βTG, NAP-2, IL-8

Receptors

GP Ib/IX/V → VWF → Bernard-Soulier
GP VI → collagen (key)
α2β1 (Ia/IIa) → collagen
IIb/IIIa → fibrinogen → Glanzmann
PAR1/4 thrombin · P2Y₁/₁₂ ADP · TP TXA₂ · IP PGI₂

Granules

α: 50–80, via SCCS
α: fibrinogen, V, VWF, PF4, βTG, PDGF, P-selectin
Dense: 2–7, via membrane
Dense: ADP, ATP, serotonin, Ca²⁺, Mg²⁺
Lysosomes: acid phosphatase, arylsulfatase

Ultrastructure

Glycocalyx 20–30 nm
SCCS = canals, α-granule exit
DTS = Ca²⁺ + COX + TX synthase
Microtubules = disc shape (cold → round)
Actin = contraction · PS flips out

Activation Steps

Adhesion: VWF–GP Ibα, collagen–GP VI, α2β1
Aggregation: fibrinogen–αIIbβ3 (RGD)
Secretion: granules via SCCS/membrane
Shear >1000 s⁻¹ needs VWF
White clot (artery) · red clot (vein)

Opposites

TXA₂: platelet, ↓ cAMP, activates
PGI₂: endothelium, ↑ cAMP, inhibits
Gi ↓ cAMP · Gs ↑ cAMP · Gq ↑ IP₃/DAG
Adhesion (surface) ≠ aggregation (platelets)

Pathways

PLA₂ → arachidonic acid → COX → PGG₂/PGH₂ → TXA₂
TXA₂ t½ 30 s → TXB₂ → urine 11-dehydro-TXB₂
PLC → IP₃ (Ca²⁺) + DAG (PKC → pleckstrin)

Confusing Pairs

LD-CFU-Meg (progenitor) ≠ MK-I (stage)
DTS (regulates Ca²⁺) ≠ dense granules (store Ca²⁺)
SCCS ≠ DTS
βTG (platelet-only) ≠ PF4 (heparin)
VWD = plasma protein, not platelet defect

9 · Final Memory Map

🩹 PLATELETS
- Megakaryocytopoiesis
  - CMP → MEP → BFU-Meg → CFU-Meg → LD-CFU-Meg
  - Endomitosis (RUNX1, NF-E2) → 8N–32N
  - MK-I → MK-II → MK-III · DMS
- Regulation
  - TPO (liver, MPL, inverse to mass)
  - IL-3, IL-6, IL-11 · TPO mimetics
  - Inhibitors: PF4, βTG, IL-8
- Platelets
  - 150–400 × 10⁹/L · MPV 8–10 · ⅓ in spleen
  - Reticulated/stress platelets
  - Turnover 8–9 days
- Ultrastructure
  - Membrane (PS inner → outer) · glycocalyx
  - SCCS · DTS (Ca²⁺ control center)
  - Microtubules · actin microfilaments
- Receptors
  - GP Ib/IX/V–VWF · GP VI and α2β1–collagen
  - αIIbβ3–fibrinogen
  - STRs: PAR1/4, P2Y₁/₁₂, TP, α2, IP
- Granules
  - α: proteins, via SCCS
  - Dense: ADP, ATP, serotonin, Ca²⁺
  - Lysosomes
- Activation
  - Adhesion → aggregation → secretion
  - PS surface for tenase/prothrombinase
  - White vs red clot
- Pathways
  - G proteins (Gi, Gq, G12, Gs)
  - Eicosanoid: COX → TXA₂ vs PGI₂
  - IP₃–DAG · cAMP · Ca²⁺